Literature DB >> 25420917

Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease.

Eolia Brissot1, Celine Bossard1, Florent Malard1, Cécile Braudeau1, Patrice Chevallier1, Thierry Guillaume1, Jacques Delaunay1, Régis Josien1, Marc Gregoire1, Beatrice Gaugler1, Mohamad Mohty2.   

Abstract

This study investigated the role of cytokines and chemokines in aGVHD incidence and severity in 109 patients who underwent reduced-intensity conditioning allogeneic stem cell transplantation (HSCT). Among the 42 cytokines tested at d 0 HSCT, only CX3CL1 levels at d 0 HSCT were significantly associated with Grades II-IV aGVHD development (P = 0.04). Increased levels of CX3CL1 at d 20-30 and 50 post-HSCT were also significantly associated with aGVHD (P = 0.02 and P = 0.03, respectively). No such association was found before the conditioning regimen or at d 100-120 post-HSCT. As the receptor for CX3CL1 is CX3CR1, the number of CX3CR1(+) cells was determined by flow cytometry. The CX3CR1(+)CD8(+) T cell proportion was significantly higher in patients with aGVHD than those without aGVHD (P = 0.01). To investigate the distribution of the CX3CL1/CX3CR1 axis in the anatomic sites of aGVHD, CX3CL1 and CX3CR1 levels were studied by use of an in situ immunohistochemical analysis on GI biopsies of patients with intestinal aGVHD. CX3CL1 expression was increased significantly in the epithelial cells and mononuclear cells of the lamina propria. CX3CR1(+) mononuclear cells were identified in close contact with epithelial cells. These findings strongly suggest the implication of the CX3CL1/CX3CR1 axis in the pathogenesis of aGVHD. © Society for Leukocyte Biology.

Entities:  

Keywords:  allogeneic transplant; alloreactivity; endothelium; stem cell

Mesh:

Substances:

Year:  2014        PMID: 25420917     DOI: 10.1189/jlb.5HI0714-325R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  3 in total

1.  A new checkpoint in the path to GVHD? How bedside-to-bench stem cell transplant studies can inform human GVHD biology.

Authors:  Austin John Barrett
Journal:  J Leukoc Biol       Date:  2015-02       Impact factor: 4.962

2.  Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

Authors:  Molly Mercedes Ryan; Mihir Patel; Keenan Hogan; Ariel Joy Lipat; Rafaela Scandolara; Rahul Das; Charles Bruker; Jacques Galipeau; Raghavan Chinnadurai
Journal:  Transplant Cell Ther       Date:  2021-02-04

3.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.